SCHEMBL1009010

SCHEMBL1009010

CN1C=NN(c2ccccc2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
KDM4E B2RXH2 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
MAPK1 P28482 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
GLA P06280 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAOB P27338 2/20 0.35
ATM Q13315 1/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
SIGMAR1 Q99720 2/20 0.32
DRD2 P14416 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
CYP3A4 P08684 2/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3861449 0.77 MAPT (0.41) MAPTKDM4ETDP1MAPK1NPC1
SCHEMBL13183114 0.75 CHRNA7 (0.39) MAPTKDM4ETDP1MAPK1NPC1
SCHEMBL10704443 0.71 L3MBTL1 (0.37) MAPTKDM4ETDP1MAPK1NPC1
SCHEMBL10916078 0.67 NPC1 (0.36) MAPTKDM4ETDP1MAPK1NPC1
SCHEMBL21864339 0.67 SMN1; SMN2 (0.38) MAPTKDM4ETDP1MAPK1NPC1
SCHEMBL6304342 0.65 TP53 (0.48) MAPTKDM4ETDP1MAPK1NPC1
SCHEMBL44773 0.65 TP53 (0.48) MAPTKDM4ETDP1MAPK1NPC1
Iodide SCHEMBL2194785 0.64 MEN1 (0.36) MAPTKDM4ETDP1MAPK1NPC1
SCHEMBL1047772 0.61
SCHEMBL22906223 0.61 L3MBTL1 (0.38) MAPTKDM4ETDP1MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043460-A1 PHOSPHORESCENT C^C* PLATINUM(II) COMPLEXES WITH BORONIC LIGANDS AND THEIR USE AS EMITTERS IN OLEDS Technische Universität Dresden (DE) 2024-02-08 US disclosed
EP-2268652-B1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-12-19 EP disclosed
EP-2268652-A2 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2011-01-05 EP disclosed
WO-2009118475-A2 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-01 WO disclosed
US-7501521-B2 Metal-complex compound and organic electroluminescence device using the compound IDEMITSU KOSAN CO., LTD. (JP) 2009-03-10 US disclosed
US-20070141397-A1 TRANSITION METAL COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE COMPOUND IDEMITSU KOSAN CO., LTD (JP) 2007-06-21 US disclosed
US-20070135652-A1 METAL-COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135652-A1 METAL-COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE COMPOUND EMC2, EMC1, L1CAM MAPT 591/4885KDM4E 1456/4885TDP1 4130/4885
US-20240043460-A1 PHOSPHORESCENT C^C* PLATINUM(II) COMPLEXES WITH BORONIC LIGANDS AND THEIR USE AS EMITTERS IN OLEDS ORC3, OCIAD2, CYCS MAPT 1947/4885KDM4E 4837/4885TDP1 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.